Scaling Laws in Cancer: The Dynamic Behaviour of the Power Exponent p by Guiot, Caterina et al.
C. Guiot et al.: “Scaling Laws in Cancer” 
 1
Scaling Laws in Cancer: The Dynamic Behaviour of the Power Exponent p  
 
 
Caterina Guiot 1,2, Pier Paolo Delsanto 2,3, Yuri Mansury 4 and Thomas S. Deisboeck 4,* 
 
Affiliations: 1 Dip. Neuroscience, Università di Torino, Italy and 2 INFM, sezioni di Torino 
Università e Politecnico, Italy ; 3 Dip. Fisica, Politecnico di Torino, Italy; 4 Complex Biosystems 
Modeling Laboratory, Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging, 
Charlestown, MA 02129, USA. 
 
* Corresponding Author: 
Thomas S. Deisboeck, M.D.  
Complex Biosystems Modeling Laboratory (CBML)  
Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging  
Massachusetts General Hospital-East, 2301  
Bldg. 149, 13th Street  
Charlestown, MA 02129 
Tel: 617-724-1845 
Fax:  617-726-5079  
Email: deisboec@helix.mgh.harvard.edu  
 
  
 
 
 
Abstract 
 
We have previously reported that a ‘universal’ growth law with fixed scaling exponent p, as 
proposed by West and collaborators for all living organisms, appears to be able to describe also the 
growth of tumors in vivo. Here, we investigate in more detail the dynamic behaviour of p using data 
from the literature. We show that p initially decreases before it again increases up to or even 
beyond 3/4. These results support the notion that p can vary over time and yet its dynamics are 
independent from the cancer type. We argue that this behaviour reflects the underlying evolving 
tumorigenesis in that the minimum of p signals the emergence of a fractal-like distribution network 
corresponding to the ‘angiogenetic switch’ towards a perfusion-dominated nutrient supply 
mechanism.  
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Introduction 
 
In a previous paper we reported that West et al.’s model of ‘universal growth’ (West et al, 2001) 
can also describe the growth dynamics of experimental in vivo tumors and, furthermore, that it can 
also be applied to selected data from experimental tumors as well as clinical cancer data (Guiot et 
al, 2003). In that study, the scaling exponent p is assumed to be fixed over time. Here, we introduce 
a modification to our tumor growth model allowing the exponent p to vary dynamically and 
continuously over time to reflect changes in the nutrient-supply mechanisms during tumorigenesis. 
Using our dynamic framework, we investigate biomedical data reported in the literature to test the 
validity of the proposed mechanisms.  
According to West et al (2001), the actual mass m and its rate of growth, dm/dt, are non-
linearly related: 
 
                                                ))(1(/ 1 pp
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where M is the asymptotic value of m(t) and a is a parameter related to the metabolic rate of the 
particular tumor cell line. It can be shown using Eq. (1) that m(t) exhibits an inflection point at t = 
t’ corresponding to m = m’, which depends on the value of p. The simplest way to determine m’ is 
to plot the experimental values of m and dm/dt in a cartesian plane with m as abscissa and dm/dt as 
ordinate. In fact the curve dm/dt vs m reaches a maximum at m = m’, which can be accurately 
identified. By assuming a dynamically-changing scaling exponent p = p(t) , but with a slow rate of 
change in the time interval around t’ , it follows that: 
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West et al argue that the main mechanism for nutrient supply is related to the fractal-like 
distribution network, and propose the exponent p = 3/4 as a universal scaling factor. For tumors, 
this assumption implies the presence of an angiogenetic network, hence primarily corresponds to 
active perfusion for tumor growth in vivo. Determining the proper value of the scaling exponent p, 
however, remains a controversial issue. For example, a recent paper (Dodds et al, 2001) shows that 
p = 3/4 does not yield a significantly better fit of all available data than p = 2/3 (which derives from 
a simple dimensional analysis).  
 
 
Materials and Methods 
 
To investigate the behaviour of the power exponent p in experimental in vivo tumors, we examine 
data reported in Steel (1977). In order to estimate the optimal value of p, instead of assuming it 
fixed ‘ab initio’, we solve Eq. (2) for p using the aforementioned data to estimate values of µ and 
dµ/dt from the growth curves and then iteratively compute the value of p for which the difference 
between the predicted and observed values is smallest. In principle the value of b, which is a 
biological parameter and is expected to depend on the cell line, should be independently measured. 
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Since direct measures are not available at the moment, we first assume a tentative constant value for 
b, and then perform a recursive, autoconsistent procedure to estimate p at any time. Then the value 
of b is changed and the procedure repeated until a satisfactory “best fit” is reached for both p and b. 
 
 
Results 
 
Using the procedure outlined above, we obtain the p(t) plots presented in Fig. 1. In this study here, 
we investigate three out of five cell lines of tumors growing in mice as reported in Steel (1977)1. 
Note that, regardless of the cancer type, the scaling exponent p now changes dynamically, i.e., it 
initially decreases to a minimum before it eventually rises again. From our formalism or, directly 
from Fig. 1, it appears to be possible to predict the time of onset for a perfusion-dominated nutrient 
mechanism (i.e., angiogenesis). The procedure can be further refined by reformulating the problem 
in terms of dimensionless rescaled variables, such as τ and r in Eqs. (1) and (2) of Guiot et al 
(2003), respectively, but with p assumed to vary dynamically as a function of time. In accordance 
with the results of Guiot et al (2003), this should strongly enhance the similarity of the plots of Fig. 
1. Also the inflection times, which vary in the figure from 5.3 to 14.2 days, should fall once the 
rescaled time τ is confined within a much narrower range (from about 0.21 to 0.39, in a preliminary 
evaluation). The τ range for inflection may be further reduced once more uniform starting times are 
considered (work in progress). 
 
Figure 1. 
 
                                                 
1 Data from the remaining two cell lines cannot be used for this procedure since the short duration of these two 
experimental series does not allow properly estimating the tumor mass at the inflection point. 
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Discussion 
 
In this study, we report several interesting findings from a tumor biology perspective. We found 
first that there was an initial decrease in the scaling exponent p, likely caused by a rapid onset of 
volumetric tumor growth (Vtotal) after in vivo implantation. Secondly, we argue that the 
development of an effective vascular supply network, in agreement with West et al.’s conjecture, 
does lead to the observed increase of p. We thus further hypothesize that the curve’s inflection 
point signals the switch in the dominant nutrient-replenishment mechanism from passive diffusion 
to active perfusion conferred by angiogenesis. It therefore fits, that this transition occurs in the three 
cell lines investigated here at an average tumor diameter of 6.6 mm (± 1.6 STD) which is beyond 
the threshold of 2-3 mm in tumor diameter that Folkman (1971) had argued would prompt the onset 
of angiogenesis. It is thus less surprising that when fitting the data from Torres Filho et al. (1995), 
who implanted lewis lung carcinoma cell spheroids into the dorsal skinfold chamber of CB6 mice, 
we found that the inflection of p occurs at approximately Day 6 post-tumor implantation, i.e., when 
the vessel density had reportedly reached already 81 percent of its maximum value. Moreover, in 
this study here, values for p beyond the anticipated 0.75 may suggest that active perfusion (p =3/4) 
is complemented by another supply mechanisms, likely by passive diffusion, when vascular density 
approaches its plateau phase. We further argue that such an increased surface diffusion can be 
explained by the onset of central apoptosis and necrosis, which should reduce the actively 
metabolizing tumor (cell) volume (Va) while restricting it to the highly proliferating tumor surface, 
and hence effectively raises the [S/Va] ratio. In addition, we found, that for the data analyzed here, 
this dynamic p-behaviour appears to be independent of cancer type. It is also noteworthy that the 
absolute time τ at which p reaches its minimum turns out to be very similar across the different 
tumor cell lines. Together, these findings further support our conjecture about the universality of the 
tumor growth model.  
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Based on the presented results we argue that the scaling exponent p shows distinct dynamic 
patterns in vivo and that such monitoring of p may be of interest if the angiogenetic switch is to be 
exploited for diagnostic or therapeutic purposes. More specific experiments are called for in order 
to test these hypotheses, given their important implications for cancer research. 
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Figure Caption 
 
Figure 1. Estimation of the scaling exponent p vs. time. Data from Steel (1977) refer to three 
different tumor cell lines implanted in mice. 
 
 
Figure 1. 
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